Overview
Dr. Mamonkin is a translational immunologist focused on engineering cell therapies for cancer and other diseases. Together with his team, he has developed chimeric antigen receptor (CAR) T cells targeting CD5, CD7, and other antigens in leukemia and lymphoma and translated them to first-in-human clinical trials in patients with treatment-resistant cancers (NCT03081910, NCT03690011, NCT04219163, NCT07220993).
His laboratory develops new cell platforms for autologous and off-the-shelf therapies for cancer, immune disorders, and regenerative medicine. These therapies are engineered for optimal activity and resistance to host immune rejection. Clinical translation of best approaches is the ultimate goal of Dr. Mamonkin’s team, paired with state-of-the-art correlative studies in patients treated with experimental cell therapies. Pediatric diseases are a special focus of the laboratory as Dr. Mamonkin directs translational development of pediatric cell therapies at Columbia.
Research interests of the group extend beyond the malignancy into auto- and alloimmune diseases and regenerative medicine. The laboratory has been funded by numerous awards from NIH, LLS/BCU, Stand UP to Cancer, CPRIT, CZ Biohub, and other mechanisms.
Academic Appointments
- Associate Professor of Pediatric Immunology (in Pediatrics)
Administrative Titles
- Principal Investigator, Columbia Institute for Cell Engineering and Therapy (CICET)
- Director of Laboratory and Translational Research in Pediatric Hematology, Oncology, and Stem Cell Transplantation
Credentials & Experience
Education & Training
- Specialist, 2006 Molecular Biology, Novosibirsk State University (NSU)
- PhD, 2013 Immunology, Baylor College of Medicine
Committees, Societies, Councils
- Member, Herbert Irving Comprehensive Cancer Center (TBM)
Research
Research Interests
- Alloimmunity
- Autoimmunity
- Brain and Solid Tumors
- CAR T Cells
- Clinical Trials
- Engineered Cell Therapies
- Leukemia and lymphoma
For a complete list of publications, please visit PubMed.gov